Chengdu Shibeikang Biomedical Wins Global Drug R&D Award
News related to:Chengdu Shibeikang Biomedical Technology Co., Ltd · 2 min read
The award, presented by Aroop Zutshi, Global President & Managing Partner, and Mr. Meng Yi, Chairman of the Executive Committee of the Frost & Sullivan Growth Strategy Expert Committee, recognized SBK's outstanding contributions in the field of innovative drug development.
SBK's research activities primarily focus on cardiovascular, cerebrovascular, and respiratory diseases, with efforts directed toward the discovery and development of innovative therapeutic candidates. The company has established a robust research and development pipeline, focusing on biological pathways associated with thrombotic diseases, including areas related to lipid metabolism, platelet activation, and coagulation mechanisms. Through its internal R&D processes, SBK is advancing multiple candidate programs and continues to explore innovative approaches in drug discovery and development.
In the cardiovascular and cerebrovascular research areas, SBK has developed candidate programs targeting disease-related biological mechanisms and continues to conduct research activities to support future clinical development. In the respiratory research field, the company focuses on airway mucus regulation mechanisms and conducts research related to respiratory conditions, including COPD, asthma, allergic rhinitis, and post-infectious cough. SBK is developing candidate programs across multiple formulation approaches, including injectable, oral, nebulized, and spray formulations.
The company has also developed its proprietary A-MetaForge™ AI Metabolism Differentiation Platform, which is designed to support research activities related to metabolic characteristics of candidate molecules and provide AI-assisted analysis and optimization capabilities for innovative drug discovery. By integrating computational approaches with experimental research, the platform aims to support efficiency and innovation in the drug development process.
SBK's commitment to innovative drug development is evident in its ongoing research and development activities in cardiovascular, cerebrovascular, and respiratory disease areas. The company continues to explore opportunities to advance innovative drug candidates through scientific and regulatory development pathways.
Frost & Sullivan's evaluation process, which includes industry research and assessment of companies in the cardiovascular, cerebrovascular, and respiratory new drug R&D sector, highlights SBK's achievements. The award selection process involves review and assessment by an independent judging panel composed of industry experts, investment professionals, financial experts, and business leaders.